LMR Partners LLP bought a new position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 400,000 shares of the company's stock, valued at approximately $3,264,000. LMR Partners LLP owned about 0.11% of Bausch Health Companies as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mackenzie Financial Corp boosted its stake in shares of Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company's stock worth $16,612,000 after acquiring an additional 1,252,834 shares in the last quarter. Clearline Capital LP purchased a new position in Bausch Health Companies during the second quarter worth approximately $6,881,000. Blair William & Co. IL grew its holdings in Bausch Health Companies by 5.0% in the first quarter. Blair William & Co. IL now owns 84,245 shares of the company's stock valued at $894,000 after purchasing an additional 4,000 shares during the period. Intact Investment Management Inc. acquired a new position in shares of Bausch Health Companies during the 3rd quarter worth approximately $1,543,000. Finally, Vanguard Group Inc. lifted its position in shares of Bausch Health Companies by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 11,713,993 shares of the company's stock valued at $124,285,000 after buying an additional 114,862 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.
Bausch Health Companies Stock Performance
NYSE:BHC traded down $0.19 on Tuesday, hitting $8.20. The stock had a trading volume of 1,131,085 shares, compared to its average volume of 2,883,356. The company has a fifty day moving average price of $8.22 and a two-hundred day moving average price of $7.09. Bausch Health Companies Inc. has a 1-year low of $3.96 and a 1-year high of $11.46.
Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the company posted $1.03 EPS. The company's quarterly revenue was up 12.2% on a year-over-year basis. Analysts forecast that Bausch Health Companies Inc. will post 3.73 EPS for the current year.
Insider Buying and Selling at Bausch Health Companies
In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the transaction, the executive vice president now directly owns 435,198 shares of the company's stock, valued at $2,702,579.58. The trade was a 2.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 8.12% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. Truist Financial reduced their price objective on shares of Bausch Health Companies from $8.00 to $7.00 and set a "hold" rating for the company in a research report on Thursday, July 25th. Piper Sandler cut Bausch Health Companies from a "neutral" rating to an "underweight" rating and reduced their target price for the company from $9.00 to $3.00 in a report on Friday, August 2nd. Royal Bank of Canada boosted their price target on Bausch Health Companies from $10.00 to $11.00 and gave the stock a "sector perform" rating in a research report on Friday, November 1st. Jefferies Financial Group reduced their price objective on Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, August 7th. Finally, Scotiabank dropped their target price on shares of Bausch Health Companies from $10.00 to $8.50 and set a "sector perform" rating for the company in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $7.75.
Check Out Our Latest Report on Bausch Health Companies
About Bausch Health Companies
(
Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
